Fibrosis, the formation of scar tissue in the liver, is a manifestation of chronic liver conditions that can eventually modify and interrupt blood flow, causing cirrhosis and impaired organ function. Late-stage fibrosis is irreversible, but the early stages are often asymptomatic, so by the time the disease is detected it’s often too late for intervention.
Available methods of diagnosing fibrosis and cirrhosis can be invasive, expensive, and imprecise. By using Doppler ultrasound scans, a widely available, non-invasive test that measures blood flow, Precision MedCare’s technology can be used in a variety of clinical settings. The algorithm analyzes how blood flow dynamics are impaired by liver rigidity or stiffness, reflecting the condition of the organ as a whole and eliminating the issue of biopsy sampling error. Medical professionals can use the system to diagnose the precise stage of fibrosis with high accuracy. Precision MedCare, LLC, has so far received funding to test the technology in China, where liver diseases affect an estimated 300 million people.